Negendank W
Department of NMR and Medical Spectroscopy, Fox Chase Cancer Center, Philadelphia, PA 19111.
NMR Biomed. 1992 Sep-Oct;5(5):303-24. doi: 10.1002/nbm.1940050518.
The literature describing 31P, 1H, 13C, 23Na and 19F MRS in vivo in human cancers is reviewed. Cancers have typical metabolic characteristics in 31P and 1H MRS including high levels of phospholipid metabolites and a cellular pH more alkaline than normal. These alone are not specific for cancer but are diagnostic in appropriate clinical settings. Some metabolic characteristics appear to be prognostic indices and correlation with treatment response is emerging as an important potentially cost-effective use of MRS in oncology. 19F MRS examines pharmacokinetics of 5-fluorouracil and by demonstrating its retention predicts response of a cancer to treatment. Current needs include improvement of diagnostic specificity by use of techniques like multivoxel MRS, proton decoupling of 31P, short echo time and fat-suppressed 1H MRS, 13C MRS direct or via 1H-observe, and statistical analysis of multiple spectral features. Trials in large populations in well defined clinical settings are needed to determine if MRS can provide independent prognostic indices useful in cancer management.
本文综述了有关人体癌症的31P、1H、13C、23Na和19F磁共振波谱(MRS)活体研究文献。癌症在31P和1H MRS中具有典型的代谢特征,包括磷脂代谢物水平升高以及细胞内pH值比正常情况更偏碱性。这些特征本身并非癌症所特有,但在适当的临床环境中具有诊断价值。一些代谢特征似乎是预后指标,并且与治疗反应的相关性正逐渐成为MRS在肿瘤学中一种重要的、潜在的具有成本效益的应用。19F MRS可检测5-氟尿嘧啶的药代动力学,并通过显示其滞留情况预测癌症对治疗的反应。当前的需求包括通过使用多体素MRS、31P的质子去耦、短回波时间和脂肪抑制1H MRS、直接或通过1H观测的13C MRS以及多种光谱特征的统计分析等技术来提高诊断特异性。需要在明确界定的临床环境中对大量人群进行试验,以确定MRS是否能够提供对癌症管理有用的独立预后指标。